From clinical breakthroughs in multiple sclerosis to a fast-growing alcohol detox brand, Quantum BioPharma is bridging biotech innovation with real-world impact.
A Biopharma Platform Tackling Today’s Toughest Health Challenges
Quantum BioPharma Ltd. (NASDAQ: QNTM | CSE: QNTM) is emerging as a dynamic force in the biotechnology sector, developing solutions for two major public health issues: neurodegenerative diseases and alcohol misuse. With a diversified pipeline spanning prescription drugs and over-the-counter consumer products, the company is building an integrated portfolio capable of delivering both near-term commercial gains and long-term medical breakthroughs.
The company’s strategy is uniquely positioned at the intersection of science, innovation, and unmet need — making it one of the few small-cap biotechs advancing both FDA-bound therapeutics and consumer-ready wellness products simultaneously.
Lucid-MS: Targeting the Root Cause of Multiple Sclerosis
At the heart of Quantum’s pharmaceutical program is Lucid-MS, a patented new chemical entity showing early promise in treating multiple sclerosis (MS). Unlike conventional MS drugs that focus on managing inflammation, Lucid-MS addresses the core driver of long-term disability in MS: the breakdown of the myelin sheath — the protective layer around nerve fibers.
Following a successful Phase 1 clinical trial, the drug has been deemed safe and well-tolerated, with therapeutic blood levels observed in healthy participants. Quantum is now preparing to launch a Phase 2 trial in 2026, targeting efficacy in MS patients.
What makes Lucid-MS even more distinctive is Quantum’s collaborative study with Massachusetts General Hospital (MGH), featuring scientists from Harvard Medical School, to validate advanced PET imaging as a way to monitor demyelination in real time. This partnership elevates both the scientific credibility and clinical precision behind Lucid-MS, positioning it as a next-generation therapeutic candidate in a $27 billion global MS treatment market.
unbuzzd™: A Consumer Wellness Product with Scientific Backing
In parallel with its clinical pipeline, Quantum BioPharma is making significant inroads in the consumer wellness market through unbuzzd™, an over-the-counter alcohol detox and recovery beverage developed by its spinout, Celly Nutrition Corp. The product, a fast-acting powder stick formulated by pharmacology experts, is designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
unbuzzd™ is already making retail waves. Backed by a double-blind, placebo-controlled clinical trial, the beverage demonstrated that it could reduce blood alcohol concentration (BAC) over 40% faster than placebo in many subjects. It’s now available via Amazon and unbuzzd.com, with retail expansion underway in the U.S., Puerto Rico, and the Caribbean through a new distribution agreement with FUSION Distribution Group.
Most recently, unbuzzd™ entered a landmark partnership with AATAC, one of the largest retail networks in the U.S., which connects the product to over 80,000 convenience store locations. This expansion gives unbuzzd™ exposure to leading chains like 7-Eleven, Circle K, Shell, and ampm — significantly scaling its retail footprint.
Multiple Value Streams, One Vision
Quantum BioPharma holds 25.71% ownership in Celly Nutrition and receives up to 7% in royalties from unbuzzd™ sales until a $250M threshold is met — and 3% in perpetuity thereafter. This structure offers upside exposure to the high-growth consumer market while maintaining strategic focus on the pharmaceutical pipeline.
With an improved cash position, enhanced operational efficiency, and momentum across both drug development and consumer wellness fronts, the company is now advancing toward key inflection points on multiple fronts.
A Biotech Story Worth Watching
With a first-in-class MS treatment advancing toward Phase 2 trials, a consumer product already on shelves and gaining market traction, and elite partnerships with global institutions like Harvard and AATAC — Quantum BioPharma stands apart in the small-cap biotech landscape.
It’s not just a company developing drugs. It’s building a platform for impact, backed by scientific validation and commercial momentum.
YOUR NEXT STEPS
Visit $QNTM HUB On AGORACOM: https://agoracom.com/ir/Quantumbiopharma
Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile
Visit $QNTM Official Verified Discussion Forum On AGORACOM:
https://agoracom.com/ir/Quantumbiopharma/forums/discussion
Watch $QNTM Videos On AGORACOM YouTube Channel:
https://studio.youtube.com/playlist/PLfL457LW0vdK6S1r-_VHqbuWQNDV4fV-D/videos
DISCLAIMER AND DISCLOSURE
This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)
AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) . As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients. In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.
Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations. These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.
